Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Analysis 4.5. Comparison 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxinepyrimethamine,<br />
Outcome 5 P. vivax parasitaemia by day 42.<br />
Review: <strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria<br />
Comparison: 4 Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine<br />
Outcome: 5 P. vivax parasitaemia by day 42<br />
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio<br />
1 Participants with P. falciparum mono-infection at baseline<br />
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI<br />
Karunajeewa 2007 PNG 27/100 56/94 100.0 % 0.45 [ 0.32, 0.65 ]<br />
Subtotal (95% CI) 100 94 100.0 % 0.45 [ 0.32, 0.65 ]<br />
Total events: 27 (DHA-P), 56 (AS+SP)<br />
Heterogeneity: not applicable<br />
Test <strong>for</strong> overall effect: Z = 4.28 (P = 0.000019)<br />
2 Participants with P. vivax P. falciparum at baseline<br />
Karunajeewa 2007 PNG 11/36 26/39 100.0 % 0.46 [ 0.27, 0.79 ]<br />
Subtotal (95% CI) 36 39 100.0 % 0.46 [ 0.27, 0.79 ]<br />
Total events: 11 (DHA-P), 26 (AS+SP)<br />
Heterogeneity: not applicable<br />
Test <strong>for</strong> overall effect: Z = 2.83 (P = 0.0046)<br />
0.01 0.1 1 10 100<br />
Favours DHA-P Favours AS+SP<br />
Analysis 5.1. Comparison 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxinepyrimethamine,<br />
Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.<br />
Review: <strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria<br />
Comparison: 5 Dihydroartemisinin-piperaquine vs Amodiaquine plus sulfadoxine-pyrimethamine<br />
Outcome: 1 Total Failure (P. falciparum) Day 28 PCR unadjusted<br />
Study or subgroup DHA-P AQ+SP Risk Ratio Weight Risk Ratio<br />
1 Africa<br />
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI<br />
Karema 2004 RWA 24/250 66/255 85.6 % 0.37 [ 0.24, 0.57 ]<br />
Zongo 2007 BFA 4/172 11/171 14.4 % 0.36 [ 0.12, 1.11 ]<br />
0.01 0.1 1 10 100<br />
Favours DHA-P Favours AQ+SP<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
151